Chineseinvestors.com Inc. (fka CIIX)

[236T568]

yet another CIIX paid research report:

http://nebula.wsimg.com/edb88e82e330f4a4501ca4ebccb13f63?AccessKeyId=F7205B59A244F1B3EF10&disposition=0&alloworigin=1

". In Compliance with SEC Rule 17B as of the date of this report Ludlow was
compensated three thousand two hundred dollars and thirty thousand restricted common shares for ongoing media
advisory services, and thus should be considered a possible conflict of interest when reviewing this report and
information. Ludlow, or its affiliates, may hold a position in above securities from time to time, and thus should be
considered a possible conflict of interest when reviewing this report and information. These investments may involve a
high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all
investments"

CIIX Issued $1.50 to $2.00 Price Target

I personally think CIIX could go way higher then this price projection if skin care line takes off


Last Updated: July 31, 2017



Ludlow Research Initiates Coverage on CIIX with Short-Term Valuation Target of $1.50 to $2.00 Per Share

(NEW YORK) – Ludlow Research initiated coverage on ChineseInvestors.com, Inc. (OTCQB: CIIX), a portfolio of consumer-packaged goods and brands, with a ‘speculative’ short-term target of $1.50 to $2.00 per share based on their pending launch of their 'CBD Magic Hemp Series' skin care product in China.

Files with China’s FDA

The Company recently announces that its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., has officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA).


Pending Product Launch

The new 'CBD Magic Hemp Series' skin care line is expected to launch between late August and early September 2017, positioning CBD Biotechnology as a first-mover in an untapped segment of China's skin care industry.

http://www.ludlowresearch.com/reports.html